In a groundbreaking study published in eLife, researchers from The University of Texas at Austin and Imperial College London have identified a novel mechanism to overcome the stubborn obstacle of antibiotic resistance by dismantling a key bacterial defense system. This innovative approach addresses both the individual shielding mechanisms of antibiotic-resistant bacteria and their collective ability to protect neighboring, drug-sensitive microbial populations—an interaction known as cross-protection. By disabling these bacterial safeguards, the study unveils a promising avenue to restore the efficacy of existing antibiotics, potentially revolutionizing the treatment of complex infections, notably those prevalent in cystic fibrosis patients.
Antibiotic resistance represents one of the most formidable challenges confronting modern medicine, with certain pathogens developing insurmountable defenses against nearly all known antibiotics. Even more insidious is the phenomenon of cross-protection wherein resistant bacteria degrade antibiotics in their immediate environment, effectively creating a drug-free haven that shelters susceptible bacteria from eradication. This communal resistance complicates infection control and accelerates the persistence and evolution of multi-drug resistant strains within polymicrobial communities.
The research, spearheaded by Nikol Kadeřábková and Chris Furniss, pivots on targeting a crucial protein-folding system vital for the functionality of bacterial resistance enzymes, especially β-lactamases. These enzymes, produced by pathogens such as Stenotrophomonas maltophilia, dismantle β-lactam antibiotics—widely used drugs including penicillins and cephalosporins—thereby neutralizing their therapeutic impact. The premise builds on the concept that by obstructing this cellular machinery, resistance enzymes lose their functional integrity, rendering bacteria vulnerable once more to antibiotic assaults.
To simulate clinically relevant conditions, the researchers employed synthetic polymicrobial communities comprising Pseudomonas aeruginosa and Stenotrophomonas maltophilia, bacteria commonly co-isolated from cystic fibrosis lung infections. Pseudomonas aeruginosa, predominantly treated with β-lactams, frequently evolves resistance partially driven by cross-protection from S. maltophilia, a species notorious for its near pan-antibiotic resistance mediated by robust β-lactamase production. This dual-species model allowed for an intricate exploration of how disrupting protein-folding mechanisms could simultaneously sensitize both pathogens and extinguish the protective interactions between them.
Functional disruption of the protein-folding gene, achieved through precise genetic deletions, resulted in the inactivation of β-lactamases and a marked resensitization of both bacterial species to β-lactam antibiotics. These findings validate the centrality of protein folding in maintaining resistance capabilities and underscore the therapeutic potential of targeting this system. Crucially, this genetic approach also illuminated the role of cross-protection in fostering multi-species resistance, as interference with protein folding nullified the protective benefits S. maltophilia confers upon P. aeruginosa.
Beyond genetic perturbations, the study made a significant leap by demonstrating that chemical inhibitors targeting the same protein-folding system could recapitulate the effect of gene deletions. This chemical inhibition reinstated antibiotic susceptibility without the need for genetic modification, highlighting a tangible path toward drug development and clinical application. These inhibitors effectively dismantled resistance enzyme activity whilst simultaneously breaking down the defensive synergy bacteria exploit in polymicrobial infections.
To validate their approach in vivo, the researchers utilized an infected wax moth larvae model, an established proxy for bacterial pathogenesis. Treatment with the protein-folding inhibitor in combination with antibiotics conferred significantly improved outcomes by not only eradicating individual species but also impeding their cooperative resistance mechanisms. This experimental evidence strengthens the concept that interventions disrupting bacterial enzyme maturation can profoundly influence the dynamics of polymicrobial infections.
The implications of this work extend well beyond cystic fibrosis, given that protein-folding systems and β-lactamase-mediated resistance are ubiquitous across a broad spectrum of Gram-negative bacteria. By targeting a shared vulnerability, this strategy holds promise for restoring the potency of β-lactam antibiotics against a wide array of multidrug-resistant bacterial infections—offering hope amidst a global health crisis propelled by the dwindling arsenal of effective antimicrobials.
This pioneering research highlights a paradigm shift in antimicrobial strategy: instead of developing new antibiotics, it focuses on disarming bacterial resistance mechanisms to make existing drugs effective again. The precise targeting of the bacterial protein-folding apparatus that matures resistance-conferring enzymes paves the way for adjunct therapies that could be administered alongside conventional antibiotics. Such combination treatments may rejuvenate the efficacy of frontline drugs while circumventing the lengthy and costly pipeline of new antibiotic discovery.
The study also emphasizes the importance of modeling infections as complex, polymicrobial ecosystems rather than isolating single species. Real-world infections often involve intricate bacterial communities where interspecies interactions modulate drug resistance and pathogenicity. Addressing these interactions is essential for the development of therapies that can effectively disrupt cross-protection and curb the spread of resistance within microbial populations.
Looking forward, research efforts will likely focus on optimizing protein-folding inhibitors for human use, assessing potential toxicity profiles, and exploring their efficacy across diverse bacterial species and infection models. This holistic approach promises to contribute substantially to antimicrobial stewardship by revitalizing the therapeutic utility of β-lactams and potentially delaying the emergence of resistance.
“In targeting the protein-folding machinery essential for antibiotic resistance enzymes, we unlock a previously underappreciated vulnerability in multidrug-resistant pathogens,” says Despoina Mavridou, co-author and assistant professor at UT Austin. “Our findings open exciting possibilities for adjunct therapies that, when combined with standard antibiotics, could transform the treatment landscape for stubborn infections, including those complicating cystic fibrosis.”
As antibiotic-resistant infections continue to escalate globally, discoveries like this not only illuminate new scientific frontiers but also reinforce the critical need for integrated strategies tackling microbial resistance at multiple levels. By undermining both individual bacterium defenses and their collective cooperation, novel therapeutic paradigms emerge—offering a beacon of hope in the fight against one of medicine’s most urgent challenges.
Subject of Research: Cells
Article Title: Antibiotic potentiation and inhibition of cross-resistance in pathogens associated with cystic fibrosis
News Publication Date: 21-Apr-2026
Web References:
DOI 10.7554/eLife.91082.2.sa4
Image Credits: Nikol Kadeřábková
Keywords: Antibiotic resistance, Drug resistance, Cell biology, Molecular biology, Cystic fibrosis
